NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis $81.76 +0.35 (+0.43%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$81.79 +0.03 (+0.04%) As of 05/27/2026 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ANI Pharmaceuticals Stock (NASDAQ:ANIP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ANI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$81.02▼$82.5850-Day Range$72.82▼$84.6352-Week Range$57.33▼$99.50Volume335,256 shsAverage Volume391,374 shsMarket Capitalization$1.86 billionP/E Ratio20.70Dividend YieldN/APrice Target$107.33Consensus RatingModerate Buy Company Overview ANI Pharmaceuticals, Inc. is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging. ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care. Alongside its proprietary generics business, ANI provides contract development and manufacturing organization (CDMO) services, leveraging its integrated in-house capabilities in sterile and nonsterile production, analytical testing and regulatory support to meet the needs of pharmaceutical partners. Primarily serving markets in North America, ANI maintains multiple U.S. manufacturing facilities certified for complex sterile and nonsterile operations. The company collaborates with major distributors, retail pharmacies, hospitals and healthcare systems, and continues to invest in process optimization and quality systems to expand its product pipeline and support evolving patient needs.AI Generated. May Contain Errors. Read More ANI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreANIP MarketRank™: ANI Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat, and ranked 236th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingANI Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 5 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialANI Pharmaceuticals has a consensus price target of $107.33, representing about 31.3% upside from its current price of $81.76.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about ANI Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth15.27% Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 15.27% in the coming year, from $7.73 to $8.91 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 20.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.06.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 20.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.34.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.33% of the float of ANI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 7.71.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 1.66%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.86 News SentimentANI Pharmaceuticals has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ANI Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows3 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,089,066.00 in company stock.Percentage Held by Insiders8.10% of the stock of ANI Pharmaceuticals is held by insiders.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIP Stock News HeadlinesANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceMay 27 at 6:50 AM | globenewswire.comANI Pharmaceuticals (ANIP) Gets a Buy from BarclaysMay 22, 2026 | theglobeandmail.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window. | Behind the Markets (Ad)ANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive PlanMay 21, 2026 | tipranks.comQ1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals StocksMay 19, 2026 | msn.comANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They SeemMay 19, 2026 | finance.yahoo.comANI Pharmaceuticals Refocuses On Rare Disease As Buybacks And Insider Sales RiseMay 17, 2026 | finance.yahoo.comANI Pharmaceuticals (NASDAQ:ANIP) SVP Thomas Andrew Rowland Sells 459 SharesMay 14, 2026 | insidertrades.comSee More Headlines ANIP Stock Analysis - Frequently Asked Questions How have ANIP shares performed this year? ANI Pharmaceuticals' stock was trading at $78.94 at the start of the year. Since then, ANIP stock has increased by 3.6% and is now trading at $81.76. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its quarterly earnings results on Friday, May, 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals's quarterly revenue was up 20.5% on a year-over-year basis. Read the conference call transcript. Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' top institutional investors include Arrowstreet Capital Limited Partnership (2.52%), Dimensional Fund Advisors LP (2.37%), Ranger Investment Management L.P. (1.58%) and Royal Bank of Canada (0.94%). Insiders that own company stock include Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Stephen P Carey, Chad Gassert, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Krista Davis, Patrick D Walsh, Thomas Andrew Rowland, Thomas Haughey, Renee P Tannenbaum, Jeanne Thoma, Antonio R Pera and Matthew J Leonard. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings5/08/2026Today5/27/2026Jefferies Global Healthcare Conference 20266/03/2026Next Earnings (Estimated)8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ANIP's financial health is in the Red zone, according to TradeSmith. ANIP has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees600Year Founded1996Price Target and Rating Average Price Target for ANI Pharmaceuticals$107.33 High Price Target$124.00 Low Price Target$90.00 Potential Upside/Downside+31.3%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$3.95 Trailing P/E Ratio20.70 Forward P/E Ratio10.58 P/E GrowthN/ANet Income$78.34 million Net Margins9.98% Pretax Margin12.56% Return on Equity27.51% Return on Assets10.02% Debt Debt-to-Equity Ratio1.06 Current Ratio3.12 Quick Ratio2.52 Sales & Book Value Annual Sales$883.37 million Price / Sales2.11 Cash Flow$9.98 per share Price / Cash Flow8.19 Book Value$24.72 per share Price / Book3.31Miscellaneous Outstanding Shares22,750,000Free Float20,903,000Market Cap$1.86 billion OptionableOptionable Beta0.46 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ANIP) was last updated on 5/28/2026 by MarketBeat.com Staff. From Our PartnersHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
